Epidemiology, pathogenesis and prevention of congenital cytomegalovirus infection

References

• Pass RF. Cytomegalovirus. In: Fields Virology Volume 2. Knipe DM, Howley PM (Eds). Lippincott, Williams and Wilkins, PA, USA, 2675–2705 (2001).
   Google Scholar
• Griffiths PD. Strategies to prevent CMV infection in the neonate. Semin. Neonatal 7(4), 293–299 (2002).
   Google Scholar
• •Defines different strategies to be developed according to the target population — children, teenagers and adults — to prevent congenital human cytomegalovirus (HCMV) infection.
   Google Scholar
• Stagno S, Pass RF, Dworsky ME, et al. Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N Engl. J. Med. 306(16), 945–949 (1982).
   PubMed Web of Science ®Google Scholar
• •Compares the prevalence of infection and socio—economic status.
   Google Scholar
• Viral Infections in Obstetrics and Gynecology Jeffries DJ, Hudson CN (Eds). Arnold, NY, USA, 35–56 (1999).
   Google Scholar
• Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr. Infect. Dis. J. 11(2), 93–99 (1992).
   PubMed Web of Science ®Google Scholar
• •Describes the importance of clinical manifestations found in symptomatic HCMV-infected infants.
   Google Scholar
• Anderson KS, Amos CS, Boppana S, Pass R. Ocular abnormalities in congenital cytomegalovirus infection. J. Am. Optom. Assoc. 67(5), 273–278 (1996).
   PubMedGoogle Scholar
• Stratton KR, Durch JS, Lawrence RS (Eds). Committee to study priorities for vaccine development, Institute of Medicine. In: Vaccines for the 21st Century: a Toll for Decision Making. National Academy Press, Washington, USA, 165–176 (2000).
   Google Scholar
• Yow MD, Demmler GJ. Congenital cytomegalovirus disease — 20 years is long enough. N Engl J. Med. 326(10), 702–703 (1992).
   PubMed Web of Science ®Google Scholar
• Hamprecht K, Maschmann J, Vochem M, Dietz K, Speer CP, Jahn G. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 357(9255), 513–518 (2001).
   PubMed Web of Science ®Google Scholar
• Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J. Pediatr. 98(2), 281–287 (1981).
   PubMed Web of Science ®Google Scholar
• •Demonstrates for the first time the protective role of antibodies to HCMV.
   Google Scholar
• Bryant P, Morley C, Garland S, Curtis N. Cytomegalovirus transmission from breast milk in premature babies: does it matter? Arch. Dis. Child. Fetal. Neonat. 87(2), F75—F77 (2002).
   PubMedGoogle Scholar
• Stagno S, Reynolds DW, Huang ES, Thames SD, Smith RJ, Alford CA. Congenital cytomegalovirus infection. N Engl J. Med. 296(22), 1254–1258 (1977).
   PubMed Web of Science ®Google Scholar
• Mustakangas P, Sarna S, Ammala P, Muttilainen M, Koskela P, Koskiniemi M. Human cytomegalovirus seroprevalence in three socioeconomically different urban areas during the first trimester: a population-based cohort study. Int. J. Epidemiol 29(3), 587–591 (2000).
   PubMed Web of Science ®Google Scholar
• Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. J. Am. Med. Assoc. 289(8), 1008–1011 (2003).
   PubMed Web of Science ®Google Scholar
• •In a large cohort study, the authors show that naturally acquired immunity reduces the risk of congenital HCMV infection in future pregnancies. This study supports the idea that the development of a HCMV vaccine makes sense.
   Google Scholar
• Boppana SB, Rivera LB, Fowler KB, Mach M, Britt W-J. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J. Med. 344(18), 1366–1371 (2001).
   PubMed Web of Science ®Google Scholar
• ••Measuring specific neutralizing antibodies in mothers of congenitally infected infants to two HCMV reference strains and to the strains isolated from their babies, the authors demonstrate that reinfection with a different strain of HCMV can lead to symptomatic congenital infection. This constitutes a challenge for the development of a vaccine.
   Google Scholar
• Gaytant MA, Rours GI, Steegers EA, Galama JM, Semmekrot BA. Congenital cytomegalovirus infection after recurrent infection: case reports and review of the literature. Eur J Pediatr. 162(4), 248–253 (2003).
   PubMed Web of Science ®Google Scholar
• Schneeberger PM, Groenenclaal F, de Vries LS, van Loon AM, Vroom TM. Variable outcome of a congenital cytomegalovirus infection in a quadruplet after primary infection of the mother during pregnancy. Acta Paediatr 83(9), 986–989 (1994).
   PubMed Web of Science ®Google Scholar
• Fisher S, Genbacev O, Maidji E, Pereira L. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. J Viral 74(15), 6808–6820 (2000).
   Google Scholar
• •Using in vitro culture models of HCMV-infected trophoblasts, the authors suggest possible routes of HCMV transmission to the fetus.
   Google Scholar
• Griffith BB McCormick SR, Fong CK, Lavallee JT, Lucia HL, Goff E. The placenta as a site of cytomegalovirus infection in guinea-pigs. J Viral 55(2), 402–409 (1985).
   PubMed Web of Science ®Google Scholar
• Gabrielli L, Losi L, Varani S, Lazzarotto T, Eusebi V, Landini ME Complete replication of human cytomegalovirus in explants of first trimester human placenta. J. Med Viral 64(4), 499–504 (2001).
   PubMed Web of Science ®Google Scholar
• Hemmings DG, Guilbert U. Polarized release of human cytomegalovirus from placental trophoblasts. J Viral 76(13), 6710–6717 (2002).
   PubMed Web of Science ®Google Scholar
• Maidji E, Percivalle E, Gema G, Fisher S, Pereira L. Transmission of human cytomegalovirus from infected uterine microvascular endothelial cells to differentiating/invasive placental cytotrophoblasts. Virology 304(1), 53–69 (2002).
   PubMed Web of Science ®Google Scholar
• Markel G, Wolf D, Hanna J, et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J. Clin. Invest. 110(7), 943–953 (2002).
   PubMed Web of Science ®Google Scholar
• Chan G, Hemmings DG, Yurochko AD, Guilbert U. Human cytomegalovirus-caused damage to placental trophoblasts mediated by immediate-early gene-induced tumor necrosis factor-a. Am. J Pathol 161(4), 1371–1381 (2002).
   PubMed Web of Science ®Google Scholar
• Yamamoto-Tabata T, McDonagh S, Chang HT, Fisher S, Pereira L. Human cytomegalovirus interleukin-10 downregulates metalloproteinase activity and impairs endothelial cell migration and placental cytotrophoblast invasiveness in vitro. J Viral 78(6), 2831–2840 (2004).
   PubMed Web of Science ®Google Scholar
• Roizman B, Pellet PE. The Family Herpesviridae: a Brief Introduction. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott, Williams and Wilkins, PA, USA, 2381–2397 (2001).
   Google Scholar
• Landolfo S, Gariglio M, Gribaudo G, Lembo D. The human cytomegalovirus. Pharmacol Ther 98(3), 269–297 (2003).
   PubMed Web of Science ®Google Scholar
• Sinzger C, Kahl M, Laib K, et al. Tropism of human cytomegalovirus for endothelial cells is determined by a postentry step dependent on efficient translocation to the nucleus. J. Gen. Viral 81(Pt 12), 3021–3035 (2000).
   Google Scholar
• Bissinger AL, Sinzger C, Kaiserling E, Jahn G. Human cytomegalovirus as a direct pathogen: correlation of multiorgan involvement and cell distribution with clinical and pathological findings in a case of congenital inclusion disease. J. Med Viral 67(2), 200–206 (2002).
   PubMed Web of Science ®Google Scholar
• Halary F, Amara A, Lortat-Jacob H, et al. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell transinfection. Immunity 17(5), 653–664 (2002).
   PubMed Web of Science ®Google Scholar
• Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and-experienced immunocompromised hosts. J Infia. Dis. 185(12), 1723–1728 (2002).
   PubMed Web of Science ®Google Scholar
• Griffiths PD. Cytomegalovirus. In: Principles and Practice of Clinical Virology Zuckerman AJ, Banatvala JE, Pattison JR (Eds). John Wiley and Sons, London, UK, 79–116 (2000).
   Google Scholar
• Halm G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc. Natl Acad Sci. USA 95(7), 3937–3942 (1998).
   PubMed Web of Science ®Google Scholar
• Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (cTo response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity and T-cell receptor usage of pp65-specific CTL. J Viral 70(11), 7569–7579 (1996).
   Google Scholar
• Borysiewicz LK, Hickling JK, Graham S, et al. Human cytomegalovirus-specific cytotoxic T-cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J. Exp. Med. 168(3), 919–931 (1988).
   PubMed Web of Science ®Google Scholar
• Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T-cells vary in differentiation phenotype in different persistent virus infections. Nature Med. 8(4), 379–85 (2002).
   PubMed Web of Science ®Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N EngL J. Med. 333(16), 1038–1044 (1995).
   PubMed Web of Science ®Google Scholar
• Gamadia LE, Remmerswaal EB, Weel JF, Bernelman F, van Lier RA, Ten Berge IJ. Primary immune responses to human CMV: a critical role for IFN-y-producing CD4+ T-cells in protection against CMV disease. Blood 101(7), 2686–2692 (2003).
   PubMed Web of Science ®Google Scholar
• Marchant A, Appay V, Van Der Sande M, et al. Mature CD8(+) T-lymphocyte response to viral infection during fetal life. J. Clin. Invest. 111(11), 1747–1755 (2003).
   PubMed Web of Science ®Google Scholar
• •Demonstrates the expansion and the differentiation of mature HCMV-specific CD8+ T-cells in early life, which have similar characteristics to those detected in adults.
   Google Scholar
• Gibson L, Piccinini G, Lilleri D, et al. Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T-cell responses in children with congenital or postnatal human cytomegalovirus infection. J. ImmunoL 172(4), 2256–2264 (2004).
   Google Scholar
• Bukowski JF, Welsh RM. Inability of interferon to protect virus-infected cells against lysis by natural killer (NK) cells correlates with NK cell-mediated antiviral effects in vivo. J. ImmunoL 135(5), 3537–3541 (1985).
   PubMed Web of Science ®Google Scholar
• Dorner BG, Smith HR, French AR, et al. Coordinate expression of cytokines and chemokines by NK cells during murine cytomegalovirus infection. J. ImmunoL 172(5), 3119–3131 (2004).
   PubMed Web of Science ®Google Scholar
• Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N EngL J. Med. 320(26), 1731–1735 (1989).
   PubMed Web of Science ®Google Scholar
• Cauda R, Prasthofer EF, Grossi CE, Whitley RJ, Pass RF. Congenital cytomegalovirus: immunological alterations. J. Med. ViroL 23(1), 41–49 (1987).
   PubMed Web of Science ®Google Scholar
• •Reports that symptomatic HCMV-infected children had reduced natural killer cell activity against fibroblasts infected with cytomegalovirus and a defective proliferative response to cytomegalovirus antigens compared with asymptomatic patients.
   Google Scholar
• Liu YN, Curtsinger J, Donahue PR, et al. Molecular analysis of the immune response to human cytomegalovirus glycoprotein B. I. Mapping of HLA-restricted helper T-cell epitopes on gp93. J. Gen. ViroL 74(Pt 10), 2207–2214 (1993).
   Google Scholar
• Beninga J, Kropff B, Mach M. Comparative analysis of fourteen individual human cytomegalovirus proteins for helper T-cell response. J. Gen. ViroL 76(P t 1), 153–160 (1995).
   Google Scholar
• Amyes E, Hatton C, Montamat-Sicotte D, et al. Characterization of the CD4+ T-cell response to Epstein—Barr virus during primary and persistent infection. J. Exp. Med. 198(6), 903–911 (2003).
   PubMed Web of Science ®Google Scholar
• Sester M, Sester U, Gartner B, et al. Levels of virus-specific CD4 T-cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71(9), 1287–1294 (2001).
   Google Scholar
• Pass RF, Stagno S, Britt WJ, Alford CA. Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus. J. Infect. Dis. 148(6), 953–961 (1983).
   PubMed Web of Science ®Google Scholar
• Tu W, Chen S, Sharp M, et al. Persistent and selective deficiency of CD4+ T-cell immunity to cytomegalovirus in immunocompetent young children. J. ImmunoL 172(5), 3260–3267 (2004).
   PubMed Web of Science ®Google Scholar
• •Demonstrates a decreased interferon-y response to cytomegalovirus by CD4+ T-cells in asymptomatic infected children, suggesting an early blockade in the differentiation of viral-specific CD4+ T-cells.
   Google Scholar
• Lucin P, Pavic I, Polic B, Jonjic S, Koszinowski UH. y-interferon-dependent clearance of cytomegalovirus infection in salivary glands. J. Viral. 66(4), 1977–1984 (1992).
   PubMed Web of Science ®Google Scholar
• Farrell HE, Shellam GR. Protection against murine cytomegalovirus infection bypassive transfer of neutralizing and non-neutralizing monoclonal antibodies. J. Gen. ViroL 72\(Pt 1), 149–156 (1991).
   Google Scholar
• Bourne N, Schleiss MR, Bravo FJ, Bernstein DI. Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea-pig model of congenital CMV infection. J. Infect. Dis. 183(1), 59–64 (2001).
   PubMed Web of Science ®Google Scholar
• Sechet A, Bridoux F, Bauwens M, Ayache RA, Belmouaz S, Touchard G. Prevention of cytomegalovirus infection and disease in high-risk renal transplant recipients with polyvalent intravenous immunoglobulins. Transplant. Proc. 34(3), 812–813 (2002).
   PubMed Web of Science ®Google Scholar
• Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N EngL J. Med. 314(16), 1006–1010 (1986).
   PubMed Web of Science ®Google Scholar
• Bissinger AL, Oettle H, Jahn G, Neuhaus P, Sinzger C. Cytomegalovirus infection after orthotopic liver transplantation is restricted by a pre-existing antiviral immune response of the recipient. J. Med. ViroL 73(1), 45–53 (2004).
   PubMed Web of Science ®Google Scholar
• Navarro D, Lennette E, Tugizov S, Pereira L. Humoral immune response to functional regions of human cytomegalovirus glycoprotein B. J. Med. ViroL 52(4), 451–459 (1997).
   PubMed Web of Science ®Google Scholar
• Gredmark S, Soderberg-Nauder C. Human cytomegalovirus inhibits differentiation of monocytes into dendritic cells with the consequence of depressed immunological functions. J. ViroL 77(20), 10943–10956 (2003).
   PubMed Web of Science ®Google Scholar
• Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 99(8), 2913–2921 (2002).
   PubMed Web of Science ®Google Scholar
• •Demonstrates that HCMV interferes with the maturation and antigen-presenting function of dendritic cells.
   Google Scholar
• Raftery MJ, Schwab M, Eibert SM, Samstag Y, Walczak H, Schonrich G. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity 15(6), 997–1009 (2001).
   PubMed Web of Science ®Google Scholar
• Senechal B, Boruchov AM, Reagan JL, Hart DN, Young JW Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood 103(11), 4207–4215 (2004).
   PubMed Web of Science ®Google Scholar
• Shamu CE, Story CM, Rapoport TA, Ploegh HL. The pathway of US11-dependent degradation of MHC Class I heavy chains involves a ubiquitin-conjugated intermediate. J. Cell. Biol. 147(1), 45–58 (1999).
   PubMed Web of Science ®Google Scholar
• Sadasivan B, Lehner PJ, Ortmann B, Spies T, Cresswell P. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC Class I molecules with TAP Immunity 5(2), 103–114 (1996).
   Google Scholar
• Tomazin R, Boname J, Hegde NR, et al. Cytomegalovirus U52 destroys two components of the MHC Class II pathway, preventing recognition by CD4+ T-cells. Nature Med. 5(9), 1039–1043 (1999).
   PubMed Web of Science ®Google Scholar
• Hegde NR, Tomazin RA, Wisner TW, et al. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex Class II antigen presentation. J. ViroL 76(21), 10929–10941 (2002).
   PubMed Web of Science ®Google Scholar
• Park B, Kim Y, Shin J, et al. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC Class I peptide cargo for immune evasion. Immunity 20(1), 71–85 (2004).
   PubMed Web of Science ®Google Scholar
• Arrode G, Davrinche C. Dendritic cells and HCMV crosspresentation. Curr. Top. Microbial. Immunol. 276,277–294 (2003).
   PubMed Web of Science ®Google Scholar
• Tomasec P, Braud VM, Rickards C, et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 287(5455), 1031 (2000).
   PubMedGoogle Scholar
• Wang EC, McSharry B, Retiere C, et al. UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc. Nad Acad. Sci. USA 99(11), 7570–7575 (2002).
   PubMed Web of Science ®Google Scholar
• Chapman TL, Heikema AP, West AP Jr, Bjorkman PJ. Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2). Immunity 13(5), 727–736 (2000).
   PubMed Web of Science ®Google Scholar
• Saverino D, Ghiotto F, Merlo A, et al. Specific recognition of the viral protein UL18 by CD85j/LIR-1/ILT2 on CD8+ T-cells mediates the non-MHC-restricted lysis of human cytomegalovirus-infected cells. J. Immunol. 172(9), 5629–5637 (2004).
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Jones TR, Zipeto D, et al. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J. Exp. Med. 188(5), 855–866 (1998).
   PubMed Web of Science ®Google Scholar
• Spencer JV, Lockridge KM, Barry PA, et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J. Viral. 76(3), 1285–1292 (2002).
   PubMed Web of Science ®Google Scholar
• Nigro G, Anceschi MM, Cosmi EV, the Congenital Cytomegalic Disease Collaborating Group. Clinical manifestations and abnormal laboratory findings in pregnant women with primary cytomegalovirus infection. Br. J. Obs. GynecoL 110(6), 572–577 (2003).
   Web of Science ®Google Scholar
• Revello MG, Zavattoni M, Furione M, Lilleri D, Gorini G, Gerna G. Diagnosis and outcome of preconceptional and periconceptional primary human cytomegalovirus infections. J. Infect. Dis. 186(4), 553–557 (2002).
   PubMed Web of Science ®Google Scholar
• Daiminger A, Bader U, Eggers M, Lazzarotto T, Enders G. Evaluation of two novel enzyme immunoassays using recombinant antigens to detect cytomegalovirus-specific immunoglobulin M in sera from pregnant women. J. Clin. Viral. 13(3), 161–171 (1999).
   PubMed Web of Science ®Google Scholar
• Revello MG, Gerna G. Diagnosis and implications of human cytomegalovirus infection in pregnancy. Fel. Matern. Med. Rev. 11,117–134 (1999).
   Google Scholar
• Eggers M, Metzger C, Enders G. Differentiation between acute primary and recurrent human cytomegalovirus infection in pregnancy, using a microneutralization assay. J. Med. Viral. 56(4), 351–358 (1998).
   PubMed Web of Science ®Google Scholar
• Rothe M, Pepperl-Klindworth S, Lang D, et al. An antigen fragment encompassing the AD2 domains of glycoprotein B from two different strains is sufficient for differentiation of primary vs. recurrent human cytomegalovirus infection by ELISA. J. Med ViroL 65(4), 719–729 (2001).
   PubMed Web of Science ®Google Scholar
• Smith KL, Kulski JK, Cobain T, Dunstan RA. Detection of cytomegalovirus in blood donors by the polymerase chain reaction. Transfusion 33(6), 497–503 (1993).
   PubMed Web of Science ®Google Scholar
• Revello MG, Zavattoni M, Sarasini A, Percivalle E, Simoncini L, Gerna G. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J. Infect. Dis. 177(5), 1170–1175 (1998).
   PubMed Web of Science ®Google Scholar
• Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin. Microbial. Rev. 15(4), 680–715 (2002).
   PubMed Web of Science ®Google Scholar
• •• Excellent, objective and up-to-date review of the subject.
   Google Scholar
• Boppana SB, Smith RJ, Stagno S, Britt W-J. Evaluation of a microtiter plate fluorescent-antibody assay for rapid detection of human cytomegalovirus infection. J. Clin. Microbial. 30(3), 721–723 (1992).
   PubMed Web of Science ®Google Scholar
• Demmler GJ, Buffone GJ, Schimbor CM, May RA. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J. Infect. Dis. 158(6), 1177–1184 (1988).
   PubMed Web of Science ®Google Scholar
• Nelson CT, Istas AS, Wilkerson MK, Demmler GJ. PCR detection of cytomegalovirus DNA in serum as a diagnostic test for congenital cytomegalovirus infection. J. Clin. Microbial. 33(12), 3317–3318 (1995).
   PubMed Web of Science ®Google Scholar
• Revello MG, Sarasini A, Zavattoni M, Baldanti F, Gerna G. Improved prenatal diagnosis of congenital human cytomegalovirus infection by a modified nested polymerase chain reaction. J. Med. Viral. 56(1), 99–103 (1998).
   PubMed Web of Science ®Google Scholar
• Barbi M, Binda S, Primache V, et al. Cytomegalovirus DNA detection in Guthrie cards: a powerful tool for diagnosing congenital infection. J. Clin. Viral. 17(3), 159–165 (2000).
   PubMed Web of Science ®Google Scholar
• Zucca C, Binda S, Borgatti R, et al. Retrospective diagnosis of congenital cytomegalovirus infection and cortical maldevelopment. Neurology 61(5), 710–712 (2003).
   PubMed Web of Science ®Google Scholar
• Liesnard C, Donner C, Brancart F, Gosselin F, Delforge ML, Rodesch F. Prenatal diagnosis of congenital cytomegalovirus infection: prospective study of 237 pregnancies at risk. Obstet. Gynecol. 95(6 Pt 1), 881–888 (2000).
   PubMedGoogle Scholar
• •Important study that defines the recommendations for prenatal diagnosis of HCMV infection.
   Google Scholar
• Davis LE, Tweed GV, Chin TD, Miller GL. Interuterine diagnosis of cytomegalovirus infection: viral recovery from amniocentesis fluid. Am. J. Obstet. Gynecol. 109(8), 1217–1219 (1971).
   PubMed Web of Science ®Google Scholar
• Weiner CP, Grose C. Prenatal diagnosis of congenital cytomegalovirus infection by virus isolation from amniotic fluid. Am. J. Obstet. Gynecol. 163(4 Pt 1), 1253–1255 (1990).
   PubMedGoogle Scholar
• Donner C, Liesnard C, Content J, Busine A, Aderca J, Rodesch F. Prenatal diagnosis of 52 pregnancies at risk for congenital cytomegalovirus infection. Obstet. Gynecol. 82(4 Pt 1), 481–486 (1993).
   PubMedGoogle Scholar
• Revello MG, Zavattoni M, Baldanti F, Sarasini A, Paolucci S, Gerna G. Diagnostic and prognostic value of human cytomegalovirus load and IgM antibody in blood of congenitally infected newborns. J. Clin. Viral. 14(1), 57–66 (1999).
   PubMed Web of Science ®Google Scholar
• Boppana SB, Britt WJ. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J. Infect. Dis. 171(5), 1115–1121 (1995).
   PubMed Web of Science ®Google Scholar
• Bodeus M, Goubau P. Predictive value of maternal-IgG avidity for congenital human cytomegalovirus infection. J. Clin. Viral. 12(1), 3–8 (1999).
   PubMed Web of Science ®Google Scholar
• Remington JS, Klein JO (Eds). Infectious Diseases of the Fetus and Newborn Infant. WB Saunders Company, PA, USA, 389–424 (2001).
   Google Scholar
• •Clear and detailed introduction to the problem of congenital and neonatal HCMV infection.
   Google Scholar
• Gouarin S, Gault E, Vabret A, et al. Real-time PCR quantification of human cytomegalovirus DNA in amniotic fluid samples from mothers with primary infection. J. Clin. Microbial 40(5), 1767–1772 (2002).
   PubMed Web of Science ®Google Scholar
• Liesnard C, Brancart F, Delforge ML, Gosselin F, Rodesch F, Donner C. Amniotic fluid CMV load is not prognostic of congenital infection severity. 8th International gtomegalovirus Workshop. Monterey, CA, USA, 20–25 May 2001.
   Google Scholar
• Halwachs-Baumann G, Genser B, Pailer S, et al. Human cytomegalovirus load in various body fluids of congenitally infected newborns. J. Clin. Viral 25\(Suppl. 3), S81—S87 (2002).
   PubMedGoogle Scholar
• Pignatelli S, Dal Monte P, Rossini G, Lazzarotto T, Gatto MR, Landini MP Intrauterine cytomegalovirus infection and glycoprotein N (gN) genotypes. J. Clin. Viral. 28(1), 38–43 (2003).
   PubMed Web of Science ®Google Scholar
• Adler SP, Finney JW, Manganello AM, Best AM. Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: a randomized controlled trial. Pediatr Infict. Dis. J. 15(3), 240–246 (1996).
   PubMed Web of Science ®Google Scholar
• Gilbert GL, Hayes K, Hudson IL, James J. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet 1(8649), 1228–1231 (1989).
   PubMed Web of Science ®Google Scholar
• Liesnard C, Strebelle E, Englert Y. Screening standards in assisted reproductive technologies. Is the British Andrology Society recommendation to recruit cytomegalovirus negative semen donors only, a reasonable one? Hum. Reprod. 16(9), 1789–1791 (2001).
   PubMed Web of Science ®Google Scholar
• De Clercq E. Antiviral drugs in current clinical use. J. Clin. Viral. 30(2), 115–133 (2004).
   PubMed Web of Science ®Google Scholar
• Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356(9230), 645–649 (2000).
   PubMed Web of Science ®Google Scholar
• Sissons JG, Carmichael AJ. Clinical aspects and management of cytomegalovirus infection. J. Infect. 44(2), 78–83 (2002).
   PubMed Web of Science ®Google Scholar
• Nigro G, Sali E, Anceschi MM, et al. Foscarnet therapy for congenital cytomegalovirus liver fibrosis following prenatal ascites. J. Matern. Fel. Neonat. Med 15(5), 325–329 (2004).
   PubMedGoogle Scholar
• De Clercq E. Clinical potential of the acyclic nucleosides phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbial Rev. 16(4), 569–596 (2003).
   PubMed Web of Science ®Google Scholar
• Prosch S, Priemer C, Hoflich C, et al. Proteasome inhibitors: a novel tool to suppress human cytomegalovirus replication and virus-induced immune modulation. Antivir. Ther. 8(6), 555–567 (2003).
   PubMed Web of Science ®Google Scholar
• Williams SL, Hartline CB, Kushner NL, et al. In vitro activities of benzimidazole D-and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47(7), 2186–2192 (2003).
   PubMed Web of Science ®Google Scholar
• Jones TR, Lee SW, Johann SV, et al. Specific inhibition of human cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea small molecule. J. Virol. 78(3), 1289–1300 (2004).
   PubMed Web of Science ®Google Scholar
• Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J. Infect. Dis. 186(6), 760–768 (2002).
   Google Scholar
• Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homolog controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 359(6390), 85 (1992).
   PubMedGoogle Scholar
• Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188(1), 32–39 (2003).
   PubMed Web of Science ®Google Scholar
• Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbial Rev. 12(2), 286–297 (1999).
   PubMed Web of Science ®Google Scholar
• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus Type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl. J Med 331(18), 1173–1180 (1994).
   PubMed Web of Science ®Google Scholar
• Maine GT, Lazzarotto T, Landini MP New developments in the diagnosis of maternal and congenital CMV infection. Expert. Rev. Mal Diagn. 1(1), 19–29 (2001).
   PubMedGoogle Scholar
• Reigstad H, Bjerknes R, Markestad T, Myrmel H. Gancidovir therapy of congenital cytomegalovirus disease. Acta Paediatr. 81(9), 707–708 (1992).
   PubMed Web of Science ®Google Scholar
• Attard-Montalto SP, English MC, Stimmler L, Snodgrass GJ. Gancidovir treatment of congenital cytomegalovirus infection: a report of two cases. Scand. J. Infect. Dis. 25(3), 385–388 (1993).
   PubMed Web of Science ®Google Scholar
• Stronati M, Revell() MG, Cerbo RI\4, Furione M, Rondini G, Gerna G. Gancidovir therapy of congenital human cytomegalovirus hepatitis. Acta Paediatr. 84(3), 340–341 (1995).
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Cloud G, Gruber W, et al. Gancidovir treatment of symptomatic congenital cytomegalovirus infection: results of a Phase II study. J. Infect. Dis. 175(5), 1080–1086 (1997).
   PubMed Web of Science ®Google Scholar
• Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 143(1), 16–25 (2003).
   PubMed Web of Science ®Google Scholar
• Michaels MG, Greenberg DP, Sabo DL, Wald ER. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr. Infect. Dis. J. 22(6), 504–509 (2003).
   PubMed Web of Science ®Google Scholar
• Demmler GJ. Congenital cytomegalovirus infection treatment. Pediatr. Infect. Dis. J. 22(11), 1005–1006 (2003).
   PubMed Web of Science ®Google Scholar
• Prober CG, Enright AM. Congenital cytomegalovirus (CMV) infections: hats off to Alabama. J. Pediatr. 143(1), 4–6 (2003).
   PubMed Web of Science ®Google Scholar
• •Discusses results and perspectives following important studies concerning treatment of HCMV infected infants using ganciclovir.
   Google Scholar
• Whitley RJ. Congenital cytomegalovirus infection: epidemiology and treatment. Adv. Exp. Med. Biol. 549,155–160 (2004).
   PubMed Web of Science ®Google Scholar
• Cwynarski K, Ainsworth J, Cobb old M, et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97(5), 1232–1240 (2001).
   PubMed Web of Science ®Google Scholar
• Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 257(5067), 238–241 (1992).
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T-cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99(11), 3916–3922 (2002).
   PubMed Web of Science ®Google Scholar
• Einsele H, Hebart H. CMV-specific immunotherapy. Hum. ImmunoL 65(5), 558–564 (2004).
   PubMed Web of Science ®Google Scholar
• Moss PA, Cobbold M, Craddock C. The cellular immunotherapy of viral infection. Transfits. Med. 13(6), 405–415 (2003).
   PubMed Web of Science ®Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J. Med 333(16), 1038–1044 (1995).
   PubMed Web of Science ®Google Scholar
• Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunization against primary cytomegalovirus infection. Vaccine 19(11–12), 1356-1362(2001).
   Google Scholar
• Elek SD, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1(7845), 1–5 (1974).
   Google Scholar
• Plotkin SA, Furukawa T, Zygraich N, Huygelen C. Candidate cytomegalovirus strain for human vaccination. Infict. Immun.12(3), 521–527 (1975).
   Google Scholar
• Plotkin SA, Weibel RE, Alpert G, et al. Resistance of seropositive volunteers to subcutaneous challenge with low-passage human cytomegalovirus. j Infict. Dis. 151(4), 737–739 (1985).
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58(11), 1176–1178 (1994).
   PubMed Web of Science ®Google Scholar
• Pass RF, Duliege AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect. Dis. 180(4), 970–975 (1999).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Schleiss MR, Berencsi K, et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect. Dis. 185(5), 686–890 (2002).
   PubMed Web of Science ®Google Scholar
• Schleiss MR, Bourne N, Bernstein DI. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea-pig model of congenital CMV infection. J. Infect. Dis. 188(12), 1868–1874 (2003).
   PubMed Web of Science ®Google Scholar
• Marshall BC, Adler SR Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59). Viral Immunol 16(4), 491–500 (2003).
   PubMed Web of Science ®Google Scholar
• Berencsi K, Gyulai Z, Gonczol E, et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T-cell responses in human CMV-seronegative subjects. J. Infect. Dis. 183(8), 1171–1179 (2001).
   Google Scholar
• Adler SP, Plotkin SA, Gonczol E, et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J. Infect. Dis. 180(3), 843–846 (1999).
   PubMed Web of Science ®Google Scholar
• Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SR Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr. Infect. Dis. J. 21(2), 133–138 (2002).
   PubMed Web of Science ®Google Scholar
• Pepperl-Klindworth S, Frankenberg N, Plachter B. Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles. J. Clin. Viral. 25\(Suppl. 2), S75—S85 (2002).
   PubMedGoogle Scholar
• Ben Mohamed L, Krishnan R, Longmate J, et al. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA Class II restricted T(H) response. Hum. Immunol 61(8), 764–779 (2000).
   PubMed Web of Science ®Google Scholar
• Temperton NJ. DNA vaccines against cytomegalovirus: current progress. Int. J. Anti microb. Agents 19(3), 169–172 (2002).
   PubMed Web of Science ®Google Scholar